Major subsidiary Daiken Biomedical Co., Ltd. announces the board of directors' resolution to conduct a cash capital increase and issue new shares.

 Major subsidiary Daiken Biomedical Co., Ltd.
announces the board of directors' resolution to conduct
a cash capital increase and issue new shares.

1.Date of the resolution by the board of directors or decision by the
Company:2024/05/23
2.Number of shares issued:37,594,000 shares
3.Par value per share:NTD10
4.Total monetary value of the issuance:
NTD 375,940,000 (calculated at face value)
5.Issue price:NTD26.6
6.Number of shares subscribed for by employees:
In accordance with the law,10% will be reserved for subscription by employees
7.Ratio of shares subscribed for by existing shareholders:
10% of the new shares issued this time will be legally reserved for
subscription by employees, and the remainder will be available for
subscription by existing shareholders in proportion to their current
shareholdings.
8.Method for public sale and no.of shares:Not applicable
9.Handling method for fractional shares and shares unsubscripted
for by the deadline:Those who do not subscribe within the specified period
will be considered to have waived their rights, and the chairman will arrange
for specific persons to fully subscribe the shares.
10.Rights and obligations of these newly issued shares:
Same as the shares already issued.
11.Utilization of the funds from the current capital increase:
To increase operating capital and repay loans.
12.Reference date of cash capital increase and share subscription:
The chairman is authorized to determine the base date for
the capital increase.
13.Last date before book closure:Not applicable
14.Book closure starting date:Not applicable
15.Book closure ending date:Not applicable
16.Payment period:2024/05/29-2024/06/04
17.Date of the agreement with the banks to collect and deposit the proceeds:
Not applicable
18.Name of the institution designated to collect the proceeds:
Not applicable
19.Name of the bank designated to deposit the proceeds:Not applicable
20.Any other matters that need to be specified:NONE